Related Experiment Video
Updated: May 4, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Identification and physicochemical characteristics of temozolomide process-related impurities
Marta Łaszcz1, Marek Kubiszewski, Lukasz Jedynak
1Pharmaceutical Research Institute (PRI), Warszawa 01-793, Poland. m.laszcz@ifarm.eu.
Abstract:
In this article the crystal structures of the starting material TZ-5 and the key intermediate TZ-6 of temozolomide (TZ-7), an anticancer therapeutic agent, are presented, together with their spectroscopic and thermal characteristics. Both compounds crystallize in the triclinic P-1 space group. X-ray crystallography studies proved that the compound TZ-6 exists as a monohydrate. A complete structural assignment was obtained for the signals in the 1H-, 13C- and 15N-nuclear magnetic resonance spectra and the structures were confirmed by Fourier-Transform infrared and Raman spectroscopy. The article describes the importance of the high purity of TZ-6 during the small-scale plant production of TZ-7 in a desired polymorphic form III with the purity higher than 99.50%, according to an HPLC method.
Related Concept Videos
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Drug Dissolution: Requirements and Profile Comparison
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Clinically Relevant Drug Product Specifications: Methods of Establishment
Washing, Drying, and Ignition of Precipitates

